Bioconjugate structures vs. composite nanoparticulate carriers: the battle for the future of smart, effective and safe cancer management

References

[1] Muggia FM.Doxil in breast cancer.J Clin Oncol1998;16:811-2

[2] Porche DJ.Liposomal doxorubicin (doxil)..J Assoc Nurses AIDS Care1996;7:55-9

[3] Tagami T.Recent trends in clinical trials related to carrier-based drugs.J Pharm Sci2017;106:2219-26

[4] Cagel M,Bernabeu E,Zubillaga MB,Chiappetta DA.Polymeric mixed micelles as nanomedicines: achievements and perspectives.Eur J Pharm Biopharm2017;113:211-28

[5] Lammers T,Hennink WE.Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress.J Control Release2012;161:175-87

[6] Hermanson GT.Bioconjugate Techniques, 3rd Edition.Academic Press;2013;

[7] Duncan R.Polymer conjugates as anticancer nanomedicines.Nat Rev Cancer2006;6:688-701